Personalized mRNA cancer vaccine cuts melanoma death and recurrence by 42%
Top-line trial results show the personalized mRNA vaccine reduced mortality and recurrence rates in patients with melanoma.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
The story so far
3 publishers have covered this in 3 articles since 22 Oct 2026. Ars Technica published first, on 22 October at 22:12 UTC; BBC Health followed 9h 37m later. The most recent article, from The New York Times, appeared on 23 October at 09:00 UTC.
Outlets reporting it: Ars Technica (major outlet), The New York Times (major outlet), BBC Health.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
Sources
Every article we clustered into this story. Headlines link to the publisher.